Abstract 908P
Background
ACC is a heterogeneous malignancy with no standard treatment for R/M disease. Around 20% of ACC carry NOTCH1 (N1) activating mutations associated with poor prognosis. We hypothesized that Ni is an active therapy for ACC pts with N1 mutation or pathway activation.
Methods
Retrospective study of 29 R/M ACC pts with N1 mutation or pathway activation (assessed by cleaved N1 IHC) treated with Ni at MD Anderson (MDA). Ni included AL101, a gamma-secretase inhibitor, or OMP-52M51, an antibody targeting N1. Efficacy endpoints were objective response rate (ORR), clinical benefit rate (CBR), and progression-free survival (PFS) per RECIST or MDA bone criteria (for pts with bone disease only). These endpoints were assessed at two timepoints: during Ni therapy and immediately prior to Ni (pre-Ni) during systemic therapy or observation for the same pts.
Results
Out of the 29 ACC pts, 18 (62%) were males with median age 45 y (26-72 y). Of 24 genotyped ACC, 23 (96%) had N1 mutation. 15 (75%) of 20 pts with reported ACC histology had a solid component. 18 (62%) pts received AL101 and 11 (38%) received OMP-52M51. Ni was given in 2nd line or beyond in 18 (62%) pts, with the most common prior regimen being platinum-based chemotherapy (55%). The ORR to Ni was 17% (5/29), CBR was 72% (21/29) and median PFS was 4.2 mos (95%CI 2.9-8.6 mos). Tumor progression on Ni occurred on non-target lesions in 10/29 (34%) pts. 23 of 29 (79%) pts were eligible for PFS analysis immediately prior to Ni; 13 (57%) had received systemic therapy and 10 (43%) were under close observation. The median PFS on Ni vs. pre-Ni was 4.2 vs. 3 mos, respectively (HR 0.42 [95%CI 0.22-0.81], p=0.0076). Considering only the 13 pts who were on systemic therapy pre-Ni, ORR pre-Ni was 0% (0/13) and CBR was 8% (1/13). Median PFS on Ni vs. prior systemic therapy was 3.7 vs. 2.1 mos, respectively (HR 0.34 [95%CI 0.13-0.93], p= 0.029).
Conclusions
Ni has activity in ACC pts with N1 mutation or pathway activation. The efficacy of Ni compares favorably with efficacy of systemic therapies administered prior to Ni. The limited PFS and high rate of tumor progression on non-target lesions suggests Ni combination therapy may be necessary to address ACC heterogeneity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Texas MD Anderson Cancer Center.
Funding
Has not received any funding.
Disclosure
R. Ferrarotto: Financial Interests, Personal, Advisory Board: Regeneron-Sanofi, Ayala Pharmaceuticals, Bicara Therapeutics, Prelude Therapeutics, Guidepoint, Elevar Therapeutics, G1 Therapeutics, ExpertConnect, Remix; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Royalties: UptoDate; Financial Interests, Institutional, Coordinating PI: Merck, Gennentech, Pfizer, Ayala, EMD Serono; Financial Interests, Institutional, Other, Co-PI: Rakuten, Nanobiotix; Financial Interests, Institutional, Local PI: Prelude, ISA Therapeutics; Non-Financial Interests, Advisory Role: Cellestia. All other authors have declared no conflicts of interest.
Resources from the same session
889P - CT-based radiomics models to predict progression in locally advanced head and neck cancer treated with definitive chemoradiation
Presenter: Gema Bruixola
Session: Poster session 12
890P - Real-world survival outcomes and survival risk factors in elderly patients with locally advanced squamous cell carcinoma of the head and neck
Presenter: Nabil Saba
Session: Poster session 12
891P - Changing landscape of head and neck squamous cell carcinoma (HNSCC) treatment and survival in Thailand: A 13-year multicenter retrospective study of 6,319 patients
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 12
892P - Real-world data validation of university of San Diego nomogram for the prediction of benefit of intensive treatment for locoregionally advanced head and neck cancer
Presenter: Javier Caballero Daroqui
Session: Poster session 12
893P - Tumor node stage shift following leukocyte interleukin injection neoadjuvant extends overall survival in treatment-naïve locally advanced oral cavity/soft palate squamous cell carcinoma
Presenter: Jozsef Timar
Session: Poster session 12
894P - Is pathological complete response (PCR) a surrogate endpoint of overall survival in patients with technically unresectable oral cavity cancers? A real-world data study of 900 plus patients
Presenter: Shatabdi Chakraborty
Session: Poster session 12
896P - Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas
Presenter: Kai Wang
Session: Poster session 12
897P - Nanosomal docetaxel lipid suspension (NDLS) or docetaxel based neoadjuvant therapy in Head and neck squamous cell carcinoma: Post hoc analysis of a prospective, randomized study
Presenter: Darshit Shah
Session: Poster session 12
898P - Meta-analysis of two placebo-controlled trials of avasopasem manganese (AVA) in patients with locally advanced, head & neck cancer (LAHNC)
Presenter: Neal Dunlap
Session: Poster session 12